• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Saturday, February 4, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Bioengineering

Breakthrough Bioengineered Blood Vessels Enter Clinical Trials

Bioengineer by Bioengineer
May 19, 2013
in Bioengineering, Business
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Humacyte, Inc., announced the accomplishment of significant milestones in the clinical development of its innovative bioengineered blood vessel technology – the first off-the-shelf, human-derived, artificial blood vessels.

Bioengineered Vessels

The company received U.S. Food and Drug Administration (FDA) approval for an Investigational New Drug (IND) application to conduct a multi-center U.S. clinical trial to assess safety and efficacy of its innovative bioengineered blood vessel to provide vascular access for dialysis in End-Stage Renal Disease (ESRD) patients.

A multi-center, first-in-human pilot study is under way in Poland to evaluate the safety and efficacy of bioengineered vessels for dialysis access. Earlier this month, an Independent Safety Review Board completed its planned review of three-month safety data for the bioengineered blood vessels and concluded that there were no safety issues and that enrollment of additional patients should continue.

“Humacyte’s bioengineered vessel may be a superior surgical alternative to synthetic materials currently used for kidney dialysis,” said Laura E. Niklason, M.D., Ph.D., professor and vice chair of Anesthesia, professor of Biomedical Engineering, Yale University, and founder, Humacyte. “This technology is a key step for patients with end-stage renal disease and can potentially avoid surgical interventions and hospitalizations for these individuals. Further, demonstrating safety and efficacy in patients with ESRD sets the stage for follow-on development of our technology in other vascular procedures, such as replacement or bypass of diseased vessels, of vessels damaged by trauma, or for other vascular procedures.”

The first bioengineered blood vessel is intended for use in patients with chronic kidney disease, a major global health problem that affects 26 million Americans.[1] Patients that progress to end-stage renal disease require renal replacement therapy (hemodialysis or kidney transplant), and today there are more than 350,000 patients who currently require hemodialysis in the U.S.[2] Synthetic vascular grafts in these patients are prone to wall thickening that leads to graft clotting. As a result, patients are subjected to frequent hospitalization and re-operation.

“We are delighted to have met these critical milestones with the first off-the-shelf bioengineered blood vessels made from human collagen,” said Carrie S. Cox, chairman and chief executive officer, Humacyte. “Receiving approval to proceed with U.S. clinical studies is another key step towards bringing this unique technology to surgeons and patients.”

First U.S. Clinical Trial Approved

Under the FDA-approved IND, a U.S. pilot study will evaluate the use of bioengineered vessels to provide vascular access in subjects with ESRD undergoing routine kidney dialysis. Primary endpoints of this study will be safety and efficacy of the vessels at six months. “If our clinical trial outcomes are similar to our preclinical results, then the Humacyte bioengineered vessel may provide an exciting improvement over synthetic grafts for vascular surgeons and our patients,” said Jeffrey H. Lawson, M.D., Ph.D., professor of Surgery and professor in Pathology, Duke University School of Medicine (Durham, NC). Dr. Lawson, a consultant to Humacyte, will be an investigator in the U.S. trial at Duke University.
Initial European Trials Underway

In the multi-center, first-in-human study in Poland, the first patients received bioengineered vessels in December 2012, and these bioengineered vessels were first used for dialysis in February 2013. A planned interim review by an Independent Safety Review Board of clinicians was completed in April 2013. The Board’s approval to proceed confirms that additional dialysis patients may be enrolled as planned, with the goal of completing enrollment this year.

If these data are replicated in the clinic, then the bioengineered vessel is expected to be of significant benefit to both surgeons and patients by offering decreased rates of vessel clotting as compared to synthetic grafts. Such clotting is the major cause of graft failures. Humacyte believes that bioengineered vessels could potentially provide significant cost savings to the healthcare system when used in ESRD by lessening the number of complications and subsequent procedures.

Preclinical Data Presented at AHA Webinar

The results of foundational preclinical studies were presented today at an American Heart Association (AHA) Emerging Science Series webinar [American Heart Association Emerging Science Series], in a paper entitled ‘Human Acellular Vascular Grafts: Preclinical Dataset Supports Bench-to-Bedside Transition of Tissue-Engineered Grafts for Hemodialysis Vascular Access.’ Preclinical data suggest that the technology will be associated with less vessel clotting and minimal infection compared with currently available alternatives. Further information is available in an AHA press release [AHA Release].

“The fact that these bioengineered vessels contain no living cells enables simple storage onsite at hospitals, making them the first truly off-the-shelf engineered grafts that have transitioned into clinical evaluation,” said Shannon L. M. Dahl, Ph.D., co-founder and vice president, Scientific Operations, Humacyte. “In these preclinical studies, bioengineered vessels were repopulated with cells and remodeled like living tissue.”

About Bioengineered Blood Vessels

Humacyte’s bioengineered blood vessels are manufactured in a novel bioreactor system. Bioengineered vessels are decellularized, thereby rendering them non-immunogenic and implantable into any patient. These bioengineered vessels may be stored for up to 12 months under standard refrigerated conditions, including on-site in hospitals. This makes them readily available to surgeons and patients, and eliminates the wait for vessel production or shipping. Bioengineered vessels have demonstrated excellent resistance to thickening in large animal models for up to one year, and the early clinical trials that are now underway will provide safety and efficacy data in patients.

[1] https://www.kidney.org/kidneydisease/aboutckd.cfm
[2] http://www.nlm.nih.gov/medlineplus/news/fullstory_134056.html

Story Source:

The above story is reprinted from materials provided by Yahoo Finance.

Share13Tweet8Share2ShareShareShare2

Related Posts

blank

Why is the first Turkish bioengineering promotion website, Biyomuhendislik.com, so important?

October 28, 2022
blank

Hail a Ride Hands-Free: Apple Opens Siri to Outside Developers

July 18, 2019

Supreme London Offers Reward for IDing Man Who Damaged Store Sign

July 16, 2019

Marine Combat Veteran Kills 12 In Crowded California Bar

July 13, 2019
Please login to join discussion

POPULAR NEWS

  • Jean du Terrail, Senior Machine Learning Scientist at Owkin

    Nature Medicine publishes breakthrough Owkin research on the first ever use of federated learning to train deep learning models on multiple hospitals’ histopathology data

    65 shares
    Share 26 Tweet 16
  • First made-in-Singapore antibody-drug conjugate (ADC) approved to enter clinical trials

    58 shares
    Share 23 Tweet 15
  • Metal-free batteries raise hope for more sustainable and economical grids

    41 shares
    Share 16 Tweet 10
  • One-pot reaction creates versatile building block for bioactive molecules

    37 shares
    Share 15 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Health Equity Report Card pilot project to help close the care gap highlighted on World Cancer Day

Tech that turns household surfaces into touch sensors is a touch closer to application

Preference for naturally talented over hard workers emerges in childhood, HKUST researchers find

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 42 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In